Share on LinkedInShare on LinkedIn

ARTICLE · 19 DECEMBER 2019

USMCA: Amendments Remove Key Biologic And Patent Obligations

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

McCarthy Tétrault LLP provides a broad range of legal services, delivering strategic and...

View firm profile
Explore more from McCarthy Tétrault

On December 10, 2019, Canada, Mexico, and the United States formally agreed to amend the successor to NAFTA, officially known as CUSMA ...

CanadaIntellectual Property

On December 10, 2019, Canada, Mexico, and the United States formally agreed to amend the successor to NAFTA, officially known as CUSMA (short for the Canada-U.S.-Mexico Agreement) in Canada but popularly referred to as USMCA following the American acronym. Our firm's comprehensive review of the amendments can be found here. This blog focuses on changes affecting biologic drugs and patents.

CUSMA was first published in an agreed form on October 1, 2018. The version released on December 10, 2019 removes a number of key biologic drug and patent-related provisions that were agreed to in principle last year, as we wrote about here. As a result, under this revised USMCA, Canada will not be required to change its domestic patent or pharmaceutical IP regimes.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from